SGMOQ (Sangamo Therapeutics) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGMOQ Sangamo Therapeutics Inc SGMOQ
37 GF Score
Price $0.14
GF Value $0.20
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sangamo Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

SGMOQ
37GF Score
Sangamo Therapeutics Inc SGMOQ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sangamo Therapeutics (SGMOQ) Overvalued in 2026?

Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued. The current stock price of $0.14 is trading 28.9% below its estimated GF Value™ of $0.20. GuruFocus considers Sangamo Therapeutics to be Modestly Undervalued.

Key valuation signals for SGMOQ:

  • FFO:
  • GF Value™: $0.20 vs. price of $0.14 (28.9% below fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the SGMOQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sangamo Therapeutics Business Description

Other Exchanges 0R1D:UKGBY:Germany
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
37GF Score

Get the complete analysis for SGMOQ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price
$0.20
GF Value